Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Cannabis-Tobacco Co-Use Treatment Study
- Conditions
- Tobacco Use DisorderTobacco Use CessationCannabis UseCannabis Use DisorderMarijuana Use
- Interventions
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 200
- Registration Number
- NCT06883162
- Locations
- 🇺🇸
Medical University of South Carolina - Charleston, Charleston, South Carolina, United States
A Study of Varenicline in the Treatment of Visceral Sensation
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 8
- Registration Number
- NCT06854406
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
- Conditions
- Tobacco
- Interventions
- Drug: Nicotine Replacement Therapy (Nicotine patch plus NRT gum or lozenge)
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 1500
- Registration Number
- NCT06832085
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
TDCS Plus Varenicline for Smoking Cessation
- Conditions
- Tobacco SmokingNicotine Use DisorderTobacco Use DisorderSubstance Use DisordersNicotine DependenceSmoking Cessation
- Interventions
- Device: Active Transcranial Direct Current Stimulation (tDCS)Device: Sham Transcranial Direct Current Stimulation (tDCS)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 160
- Registration Number
- NCT06798324
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Efficacy of Varenicline Tartrate in Frequent Premature Ventricular Contractions
- Conditions
- Premature Ventricular Contraction (PVC)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Shanghai East Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT06780215
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
E-cigarette Cessation in Adults Who Co-use Cannabis
- Conditions
- Nicotine DependenceTobacco Use Disorder
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 105
- Registration Number
- NCT06688539
- Locations
- 🇺🇸
MUSC Charleston, Charleston, South Carolina, United States
🇺🇸MUSC Lancaster, Lancaster, South Carolina, United States
🇺🇸Behavioral Health Services of Pickens County, Pickens, South Carolina, United States
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Vikas Kotagal
- Target Recruit Count
- 102
- Registration Number
- NCT06679374
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
- Conditions
- Tobacco UseTobacco CessationInsomnia
- Interventions
- Behavioral: Experimental health intervention
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Yale University
- Target Recruit Count
- 114
- Registration Number
- NCT06609369
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder
- Conditions
- Nicotine AddictionCraving
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 200
- Registration Number
- NCT06582888
- Locations
- 🇺🇸
University California, San Diego, San Diego, California, United States
The Avenues Study: Dual Use Cessation
- Conditions
- Smoking CessationElectronic Cigarette Use
- Interventions
- Behavioral: Dual Focused Cessation CounselingBehavioral: Smoking Focused Cessation Counseling
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 500
- Registration Number
- NCT06474299
- Locations
- 🇺🇸
University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.